Changeflow GovPing Healthcare & Life Sciences USPTO Patent Application: Neurodegenerative Dis...
Routine Notice Added Final

USPTO Patent Application: Neurodegenerative Disorder Treatment

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260083766A1) detailing methods for treating neurodegenerative disorders by modulating RNA editing. The application was filed on May 16, 2025, by inventors Nandkishore Raghav Belur and Joseph Robert Mazzulli.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a USPTO patent application (US20260083766A1) for methods to treat neurodegenerative disorders by reducing nuclear aggregates and modulating adenosine-to-inosine RNA editing. The application, filed on May 16, 2025, by inventors Nandkishore Raghav Belur and Joseph Robert Mazzulli, describes administering adenosine-to-inosine editing modifiers to restore neuronal synaptic function.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on companies. However, it signals potential future developments in pharmaceutical research and development for neurodegenerative diseases. Companies in the pharmaceutical and biotechnology sectors may wish to monitor the progress of this application and related intellectual property.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS TO TREAT NEURODEGENERATIVE DISORDERS BY REDUCING NUCLEAR AGGREGATES AND MODULATING ADENOSINE-TO-INOSINE RNA EDITING

Application US20260083766A1 Kind: A1 Mar 26, 2026

Inventors

Nandkishore Raghav Belur, Joseph Robert Mazzulli

Abstract

This disclosure provides methods for treating neurodegenerative diseases and restoring neuronal synaptic function by administering adenosine-to-inosine editing modifiers.

CPC Classifications

A61K 31/7064 A61P 25/16 A61P 25/28 C12N 15/113 C12N 2310/11

Filing Date

2025-05-16

Application No.

19211071

View original document →

Named provisions

Abstract Inventors CPC Classifications

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
May 16th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083766A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development RNA Editing Modulation
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
R&D
Topics
Biotechnology Medical Research

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!